Innovative Medical Technology Venclose specializes in next-generation RF therapy solutions for chronic venous insufficiency, highlighting its focus on advanced minimally invasive treatments that appeal to healthcare providers seeking cutting-edge devices.

Strategic Industry Collaborations The company's partnership with Viant since 2019 demonstrates a commitment to developing innovative vein treatment technologies, which can be leveraged to identify joint solution opportunities or upselling advanced equipment.

Recent Acquisition Leverage Venclose was acquired by Becton, Dickinson and Company in late 2021, indicating expanding market reach and potential for integrated device solutions, making it a promising candidate for distribution channels and bundled offerings.

Growth & Investment Having raised $27 million in Series C funding and generating revenue up to $10 million, Venclose’s financial profile suggests opportunities for partnerships targeting expanding sales, product adoption, and clinical integration.

Focus on Medical Innovation With a small team of fewer than 50 employees and a strong emphasis on high-tech manufacturing, Venclose offers a niche opportunity to engage with innovative medical device providers resistant to traditional, larger-scale competitors in vein treatment.